Clinical trial · no report yet · Phase 2
NCT04216290
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
- NCT04216290 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Study of Bladder-SparIng ChemoradiatioN With Durvalumab in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Bladder Urothelial Carcinoma; Stage III Bladder Cancer AJCC v8
- Interventions
- Biopsy of Bladder; Biospecimen Collection; Cisplatin; Computed Tomography; Cystoscopy; Durvalumab; Fluorouracil; Gemcitabine Hydrochloride; Magnetic Resonance Imaging; Mitomycin; Patient Observation; Radiation Therapy
- Arms
- Step 1, Arm C (durvalumab, radiation therapy, chemotherapy) · Experimental
- Step 1, Arm D (radiation therapy, chemotherapy) · Active comparator
- Step 2, Arm E (durvalumab) · Experimental
- Step 2, Arm F (observation) · Active comparator
- Enrollment
- 11
- Primary outcomes
- Clinical complete response (CR)
- Sponsor
- National Cancer Institute (NCI)
- Start
- Mar 17, 2021
- Primary completion
- Feb 4, 2026
- Results posted
- No
- Registry record
- NCT04216290 · updated May 22, 2026